PTGS2 and early-onset autosomal dominant Alzheimer disease: Numerous studies have shown that nonsteroidal anti-inflammatory drugs (NSAIDs), which are COX-2 inhibitors, reduce the risk of developing Alzheimer’s disease and enhance learning and memory [23,24].